INCB086550 is a drug that is a small-molecule inhibitor of programmed death-ligand 1 (PD-L1). A number of antibodies against this target are already in clinical use for cancer treatment, but few small molecule drugs are known. INCB086550 enhances the T-lymphocyte mediated immune response against cancers which express PD-L1, and induces cytokine production. It has been researched for the treatment of cancers such as breast cancer and colorectal cancer.